El-sayed, A., El-Sabbagh, M., Abdelrazik, A., Arafa, M., Yassen, A. (2023). Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study. Medical Journal of Viral Hepatitis, 7.2(2), 15-22. doi: 10.21608/mjvh.2023.314932
Ahmed El-sayed; Mohamed El-Sabbagh; Ahmed Abdelrazik; Mona Arafa; Ahmed Yassen. "Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study". Medical Journal of Viral Hepatitis, 7.2, 2, 2023, 15-22. doi: 10.21608/mjvh.2023.314932
El-sayed, A., El-Sabbagh, M., Abdelrazik, A., Arafa, M., Yassen, A. (2023). 'Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study', Medical Journal of Viral Hepatitis, 7.2(2), pp. 15-22. doi: 10.21608/mjvh.2023.314932
El-sayed, A., El-Sabbagh, M., Abdelrazik, A., Arafa, M., Yassen, A. Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study. Medical Journal of Viral Hepatitis, 2023; 7.2(2): 15-22. doi: 10.21608/mjvh.2023.314932
Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study
1Tropical Medicine Department, Mansoura University
2Medical Microbiology and Immunology Department, Mansoura University, Egypt
3Tropical Medicine Department, Mansoura University, Egypt
4Tropical Medicine Department, Mansoura University, Egypt.
Abstract
Background: Coronavirus induced disease-19 (COVID-19), is a serious disease induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Liver cirrhosis and its complications are currently the ninth most common cause of death worldwide. This work aims to evaluate the impact of COVID-19 on mortality rate in patients with CLD. Patients and methods: The current study included 120 patients with COVID-19 who were distributed according to the state of the liver affection into two groups; group 1 included 60 patients with combined COVID-19 and CLD and group 2 included 60 with COVID-19 free from CLD. All the included cases were reviewed to obtain data about general history, clinical examination laboratory investigations and mortality rate. Results: Compared to COVID-19 patients without chronic liver diseases, patients with COVID-19 and chronic liver diseases had a significant mortality rate (60% versus 20% respectively). Among patients with chronic liver diseases, the mortality rate was statistically significantly higher in decompensated cirrhosis (100%) followed by patients with hepatocellular carcinoma (80%) and the lowest mortality rate was found in decompensated cirrhosis (46.7%). Multivariate regression analysis showed that increasing age, decreased albumin concentration, and increasing INR and PT were independent predictors for mortality in patients with chronic liver diseases. Conclusion: COVID-19 in patients with chronic liver diseases had worse outcomes compared to COVID -19 in patients without chronic liver diseases. Among the chronic liver diseases decompensated liver disease was linked to the worst outcome.